Guia miolo correção_Manual Conflito.
qxd 3/10/2011 15:54 Page 98
Câncer de Colo Uterino
Cisplatina + Radioterapia
Cisplatina: 40mg/m2 IV D1 Semanal até
término da radioterapia Ref. (1)
Paclitaxel + Cisplatina
Paclitaxel: 135mg/m2 IV D1 em infusão de 24 horas
Cisplatina: 75mg/m2 IV D1 a cada 21 dias
Ref. (9)
Cisplatina + Topotecano
Cisplatina: 50mg/m2 IV D1
Topotecano: 0,75mg/m2/dia IV D1 a D3 a cada 21 dias
Ref. (2)
Cisplatina + 5-Fluorouracil
Cisplatina: 75mg/m2 IV D1
5-Fluorouracil: 1000mg/m2 IV D1 a D5 a cada 21 dias
Ref. (3)
Cisplatina + Vinorelbina
Cisplatina: 80mg/m2 IV D1
2
Vinorelbina: 25mg/m IV D1, D8 a cada 21 dias
Ref. (4)
Cisplatina + Irinotecano
Cisplatina: 60mg/m2 IV D1
Irinotecano: 60mg/m2 IV D1, D8, D15
a cada 28 dias Ref. (5)
Docetaxel
Docetaxel: 100mg/m2 IV D1 a cada 21 dias
98 • Guia Prático para o Oncologista Clínico
Guia miolo correção_Manual Conflito.qxd 3/10/2011 15:54 Page 99
Paclitaxel
Paclitaxel: 175mg/m2 IV D1 a cada 21 dias
Ref. (6)
Irinotecano
Irinotecano: 125mg/m2 IV D1, D8, D15, D22 com
folga de 14 dias Ref. (7)
Topotecano
Topotecano: 1,5mg/m2/dia IV D1 a D5 a cada 21 dias
Ref. (8)
Vinorelbina
Vinorelbina: 30 mg/m2 IV semanalmente Ref. (10)
Ifosfamida
Ifosfamida: 1.200 mg/m2 ( com Mesna) IV D1 a D5 a cada 21 dias
Ref. (11)
Gencitabina
Gencitabina: 800 mg/m2 IV D1, D8 e D15 a cada 28 dias
Ref. (12)
1. Rose, P.G., et al. Concurrent cisplatin-based radiotherapy and
chemotherapy for locally advanced cervical cancer. N Engl J
Med, 1999. 340(15): p. 1144-53.
2. Long, H.J., 3rd, et al. Randomized phase III trial of cisplatin
with or without topotecan in carcinoma of the uterine
cervix: a Gynecologic Oncology Group Study. J Clin Oncol,
2005. 23(21): p. 4626-33.
3. Whitney, C.W., et al. Randomized comparison of fluorouracil
plus cisplatin versus hydroxyurea as an adjunct to radiation therapy
in stage IIB-IVA carcinoma of the cervix with negative para-aortic
lymph nodes: a Gynecologic Oncology Group and Southwest
Oncology Group study. J Clin Oncol, 1999. 17(5): p. 1339-48.
Guia Prático para o Oncologista Clínico • 99
Guia miolo correção_Manual Conflito.qxd 3/10/2011 15:54 Page 100
4. Pignata, S., et al. Phase II study of cisplatin and vinorelbine as
first-line chemotherapy in patients with carcinoma of the
uterine cervix. J Clin Oncol, 1999. 17(3): p. 756-60.
5. Chitapanarux, I., et al. Phase II clinical study of irinotecan and
cisplatin as first-line chemotherapy in metastatic or recurrent
cervical cancer. Gynecol Oncol, 2003. 89(3): p. 402-7.
6. Thigpen, T., et al. The role of paclitaxel in the management of
patients with carcinoma of the cervix. Semin Oncol, 1997.
24(1 Suppl 2): p. S2-41-S2-46.
7. Verschraegen, C.F., et al. Phase II study of irinotecan in prior
chemotherapy-treated squamous cell carcinoma of the
cervix. J Clin Oncol, 1997. 15(2): p. 625-31.
8. Muderspach, L.I., et al. A Phase II study of topotecan in patients
with squamous cell carcinoma of the cervix: a gynecologic
oncology group study. Gynecol Oncol, 2001. 81(2): p. 213-5.
9. Piccart, M.J., et al. Randomized intergroup trial of cisplatin-
paclitaxel versus cisplatin-cyclophosphamide in women
with advanced epithelial ovarian cancer: three-year results.
J Natl Cancer Inst, 2000. 92(9): p. 699-708.
10. Morris M, Brader KR, Levenback C, et al. Phase II study of
vinorelbine in advanced and recurrent squamous cell
carcinoma of the cervix. J Clin Oncol. 1998; 16:1094-1098.
11. Sutton GP, Blessing JA, McGuire WP, et al. Phase II trial of
ifosfamide and mesna in patients with advanced or
recurrent squamous carcinoma of the cervix who had never
received chemotherapy: a gynecologic oncology group
study. Am J Obstet Gynecol. 1993; 168:805-7.
12. Schilder RJ, Blessing JA, Morgan M, et al. Evaluation of
gemcitabine in patients with squamous cell carcinoma of
the cervix: A phase II study of the Gynecologic Oncology
Group. Gynecol Oncol 76:204–207, 2000.
100 • Guia Prático para o Oncologista Clínico
